The Brain Ketone Body Challenge Imaging Study
NCT03204604 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL
Last updated 2019-03-19
Summary
The Brain Ketone Body Challenge Imaging Study will measure how the brain uses different fuels. To do this, radioactive compounds will be used during Positron Emission Tomography (PET) imaging.
These compounds, called \[11C\]Acetoacetate (AcAc) and \[18F\] Fludeoxyglucose (FDG), are similar to the sugars and fats the brain already uses for fuel. These compounds safely allow researchers to see how the brain uses sugars and fats during PET scans.
Conditions
- Alzheimer Disease
Interventions
- DIETARY_SUPPLEMENT
-
Challenge A - low calorie Ensure®
Challenge A will include a low calorie Ensure shake for the participant to drink with no ketone esters (KE).
- DIETARY_SUPPLEMENT
-
Challenge B - Ensure® plus ketone esters (KE)
Challenge B will include an Ensure shake for the participant to drink with deltaG ketone ester, which has generally recognized as safe (GRAS) supplement status .
- PROCEDURE
-
PET Scan
Subject will drink the shake. Immediate recall memory testing. Subject will be placed in the scanner. Prior to PET acquisition, a low dose CT scan of the head will be obtained for attenuation correction. Patients will be injected with an intravenous bolus of up to 5-10mCi (370 MBq) (+/- 10%) of \[11C\]AcAc (over 2 minutes). This is the standard dose used in published clinical studies using \[11C\]AcAc. The PET acquisition will begin immediately after the tracer injection and last for a total of 30 minutes. 2 ml of blood will be sampled from the forearm vein at 3, 6, 8, 12, 20, and 28 minutes post \[11C\]AcAc tracer injection. This will be used for quantification of radiation estimates throughout the scan-period
- BEHAVIORAL
-
Cognitive Testing - FCSRT
The Free and Cued Selective Reminding Test (FCSRT) measures verbal memory through multiple trials of a list learning task. A list of 16 items is visually presented to the participants, who then recall as many items as possible. On subsequent trials, participants are told only those items they omitted on the previous trial. The procedure continues until the participant recalls all items on two subsequent trials. After approximately 30-minute delay, participants are asked to recall as many items as possible. The number of items recalled after the delay is then summed.
- BEHAVIORAL
-
Story Recall
Story Recall: This test is a modification of the episodic memory measure from the Wechsler Memory Scale-Revised (WMS-R). In this modified version, free recall of one short story that consists of 44 bits of information will be elicited immediately after it is read aloud to the participant and again after a thirty-minute delay. The total bits of information from the story that are recalled immediately (maximum score = 44) and after the delay interval (maximum score = 44) are recorded. Six comparable versions of this task have been validated in prior studies with older adults.
- BEHAVIORAL
-
BVRT
Benton Visual Retention Test (BVRT): The BVRT is a multiple-choice visual recognition task. Participants view a visual pattern and are then asked to select the target from an array of four patterns, three of which are distractors. It assesses visuospatial working memory. This recognition format has the advantage assessing visual memory while eliminating the influence of visuomotor and manual dexterity difficulties.
- BEHAVIORAL
-
CogState One Card Learning
The One Card Learning Test involves a visual learning task sensitive to early-stage cognitive impairment. It is one of several computerized assessments developed by CogState that assess executive function and working memory.
Sponsors & Collaborators
-
Wake Forest University Health Sciences
lead OTHER
Principal Investigators
-
Timothy R Hughes, PhD · Wake Forest University Health Sciences
Study Design
- Allocation
- RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- TRIPLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 50 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-08-08
- Primary Completion
- 2019-03-31
- Completion
- 2019-03-31
Countries
- United States
Study Locations
More Related Trials
-
Assess Fibrin in Brains With AD/ADRD
NCT05336695 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
NCT02640092 ·Status: COMPLETED ·Phase: PHASE1
-
PET Imaging of Neuroinflammation in Neurodegenerative Diseases Via a Novel Translocator Protein (TSPO) Radioligand
NCT03958630 ·Status: TERMINATED ·Phase: PHASE1
-
A Brain Imaging PET Study of [11C]-Lu AF88370 in Healthy Adult Male Participants
NCT05320302 ·Status: COMPLETED ·Phase: PHASE1
-
Imaging Tau in Alzheimer's Disease and Normal Aging
NCT03373604 ·Status: COMPLETED ·Phase: PHASE2
-
A Positron Emission Tomography (PET) Study Evaluating Brain Metabolism of a Medical Food in Alzheimer's Disease
NCT01122329 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Flortaucipir PET in Healthy Volunteers and Cognitively Impaired Subjects
NCT01992380 ·Status: COMPLETED ·Phase: PHASE1
-
FDDNP Protocol for Visualizing Brain Proteinopathies to Assist in the Diagnosis of Persons With Suspected CTE and AD
NCT04311281 ·Status: WITHDRAWN
-
A Positron Emission Tomography (PET) Study to Investigate the Brain Biodistribution of 18F GSK2647544 in Healthy Subjects to Determine Its Ability to Cross the Blood-brain-barrier.
NCT01924858 ·Status: TERMINATED ·Phase: PHASE1
-
Dysregulated CNS Inflammation After Acute Brain Injury
NCT03287557 ·Status: COMPLETED
-
Selective PET Imaging of Astrocytes and Microglia in Alzheimer's Disease
NCT05582200 ·Status: RECRUITING
-
Targeting Neuroinflammation as a Contributing Pathology in Alzheimer's Disease Dementia and Related Dementias
NCT04786223 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2
-
Health and Aging Brain Study: Health Disparities Tau Positron Emission Tomography (PET) Scan Study
NCT05076331 ·Status: UNKNOWN
-
[18F]PI-2620 Phase 3 Histopathological Study
NCT05641688 ·Status: RECRUITING ·Phase: PHASE3
-
Biodistribution, Pharmacokinetics, and Safety of F-18 THK-5351 PET in Alzheimer's Disease Patients and Healthy Subjects.(Positron Emission Tomograph )
NCT02686216 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558
NCT01217021 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
PET Scan of Brain Metabolism in Relation to Age and Disease
NCT00001972 ·Status: COMPLETED
-
Molecular PET Imaging and Plasma Biomarkers in Alzheimer´s Disease and Other Neurodegenerative Diseases
NCT06731842 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
[18F]ACI-19626 PET in TDP-43 Proteinopathies
NCT06891716 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Risk of Developing Dementia and Associated Factors in Patients With Normal Brain FDG PET
NCT04804722 ·Status: COMPLETED
-
[18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001)
NCT02562989 ·Status: COMPLETED ·Phase: PHASE1
-
Positron Emission Tomography (PET) to Study Brain Signaling
NCT00044200 ·Status: COMPLETED
-
[18F]MK-3328 as a Possible Novel Positron Emission Tomography (PET) Tracer for the Detection of Brain Amyloid Plaques (MK-3328-002)
NCT01385033 ·Status: TERMINATED ·Phase: PHASE1
-
Positron Emission Tomography of Amyloid in Alzheimer's Disease
NCT00205621 ·Status: SUSPENDED ·Phase: PHASE1
-
Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein
NCT03071224 ·Status: COMPLETED ·Phase: EARLY_PHASE1